Drug versus vaccine investment: a modelled comparison of economic incentives
Open Access
- 1 January 2013
- journal article
- Published by Springer Nature in Cost Effectiveness and Resource Allocation
- Vol. 11 (1) , 23
Abstract
Investment by manufacturers in research and development of vaccines is relatively low compared with that of pharmaceuticals. If current evaluation technologies favour drugs over vaccines, then the vaccines market becomes relatively less attractive to manufacturers.Keywords
This publication has 13 references indexed in Scilit:
- Introducing vaccination against serogroup B meningococcal disease: An economic and mathematical modelling study of potential impactVaccine, 2013
- Booster vaccination of pre-school children with reduced-antigen-content diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine co-administered with measles-mumps-rubella-varicella vaccineHuman Vaccines & Immunotherapeutics, 2012
- HIV-1 Vaccines and Adaptive Trial DesignsScience Translational Medicine, 2011
- WHO Guide for standardisation of economic evaluations of immunization programmesVaccine, 2010
- Why We Don’t Have An HIV Vaccine, And How We Can Develop OneHealth Affairs, 2009
- Market incentives, human lives, and AIDS vaccinesSocial Science & Medicine, 2007
- Long-term solutions for the problem of vaccine shortagesExpert Opinion on Biological Therapy, 2004
- The value of vaccinesVaccine, 2003
- The price of innovation: new estimates of drug development costsJournal of Health Economics, 2003
- The Intangible Value of VaccinationScience, 2002